The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05671835
Recruitment Status : Recruiting
First Posted : January 5, 2023
Last Update Posted : April 25, 2024
Information provided by (Responsible Party):
Tvardi Therapeutics, Incorporated

Brief Summary:
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).

Condition or disease Intervention/treatment Phase
Idiopathic Pulmonary Fibrosis Drug: TTI-101 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: REVERT-IPF: A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Actual Study Start Date : May 15, 2023
Estimated Primary Completion Date : March 2025
Estimated Study Completion Date : March 2025

Arm Intervention/treatment
Experimental: TTI-101 400 mg/day
Participants will receive 400 mg/day of TTI-101 twice daily (BID) for 12 weeks.
Drug: TTI-101
Orally via a tablet.

Experimental: TTI-101 800 mg/day
Participants will receive 800 mg/day of TTI-101 BID for 12 weeks.
Drug: TTI-101
Orally via a tablet.

Experimental: TTI-101 1200 mg/day
Participants will receive 1200 mg/day of TTI-101 BID for 12 weeks.
Drug: TTI-101
Orally via a tablet.

Placebo Comparator: Placebo
Participants will receive a matching placebo BID for 12 weeks.
Drug: Placebo
Orally via a tablet.

Primary Outcome Measures :
  1. Number of Participants with an Adverse Event (AE) [ Time Frame: 16 weeks ]
    Incidence of AEs, including serious AEs assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) V.5.0. Clinically significant changes between baseline and postbaseline laboratory assessments, electrocardiograms, vital signs, and physical examinations will be recorded as AEs.

Secondary Outcome Measures :
  1. Maximum Observed Plasma Concentration (Cmax) of TTI-101 [ Time Frame: Day 1 to Week 12 ]
  2. Time of Maximum Observed Plasma Concentration (tmax) of TTI-101 [ Time Frame: Day 1 to Week 12 ]
  3. Area Under the Plasma Concentration-time Curve Over a Dosing Interval (AUC[0-τ]) of TTI-101 [ Time Frame: Day 1 to Week 12 ]
  4. Trough Plasma Concentration (Cτ) of TTI-101 [ Time Frame: Day 1 to Week 12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosed with IPF based on either the 2018 American Thoracic Society (ATS)/ European Respiratory Society (ERS)/ Japanese Respiratory Society (JRS)/ Latin American Thoracic Association (ALAT) International Diagnostic Guidelines or on the 2022 updated guidelines within 7 years prior to the date of informed consent.
  2. Chest high-resolution computed tomography scan (HRCT) performed within 12 months prior to providing informed consent meeting requirements for IPF diagnosis based on 2018 or 2022 ATS/ERS/JRS/ALAT guidelines and confirmed by central review.
  3. Greater than 40% of predicted forced vital capacity (FVC) and a ratio of forced expiratory volume in 1 second (FEV1)/FVC ≥0.7 measured pre-bronchodilator during screening confirmed by central review.
  4. A predicted diffusing capacity of the lungs for carbon monoxide (DLCO) (hemoglobin [Hb] corrected) ≥25% during screening confirmed by central review.
  5. Oxygen saturation (SpO2) ≥88% with up to 4L O2/min by pulse oximetry at rest.
  6. If currently receiving nintedanib, dose must have been stable for ≥3 months prior to randomization. If participant has previously discontinued nintedanib, there is a 6-week washout period required before screening can begin.
  7. Has a life expectancy of at least 12 months.

Exclusion Criteria:

  1. Unresolved respiratory tract infection within 4 weeks (including coronavirus disease 2019 [COVID-19] infections) or an acute exacerbation of IPF within 3 months prior to screening.
  2. Planned surgery during the study.
  3. The investigator judges that there has been sustained improvement in the severity of IPF during the 12 months prior to screening, based on changes in FVC, DLCO, and/or HRCT scans of the chest.
  4. History of other types of respiratory diseases including diseases or disorders of the airways, lung parenchyma, pleural space, mediastinum, diaphragm, or chest wall that, in the opinion of the investigator, would impact the primary protocol endpoint or ability to do pulmonary function tests (PFTs), or otherwise preclude participation in the study.
  5. Likely to have lung transplantation during the study. Note: Participant may be on a lung transplant list if the investigator anticipates the participant will be able to complete the study prior to transplant.
  6. Clinically relevant and uncontrolled cardiac, hepatic, gastrointestinal, renal, endocrine, metabolic, neurologic, or psychiatric disorders that may interfere with the participant's ability to complete this study according to the investigator's judgment, or logistical challenges that, in the opinion of the investigator, preclude adequate participation in the study.
  7. History or difficulty of swallowing, malabsorption, or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the study drug.
  8. Receiving steroids (excluding topical steroids) in excess of a mean of 10 mg/day of prednisolone or its equivalent within 2 weeks prior to randomization.
  9. Received pirfenidone within 3 months prior to randomization.
  10. Smoking or vaping of any kind within 3 months of screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05671835

Layout table for location contacts
Contact: Russell Lesko Please email
Contact: Kari Anne Rowland, MS Please email

Show Show 22 study locations
Sponsors and Collaborators
Tvardi Therapeutics, Incorporated
Layout table for additonal information
Responsible Party: Tvardi Therapeutics, Incorporated Identifier: NCT05671835    
Other Study ID Numbers: TVD-101-003P
First Posted: January 5, 2023    Key Record Dates
Last Update Posted: April 25, 2024
Last Verified: February 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Tvardi Therapeutics, Incorporated:
Idiopathic Pulmonary Fibrosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Pathologic Processes
Lung Diseases, Interstitial
Lung Diseases
Respiratory Tract Diseases